Sean Gaskell - Alvotech Chief Officer

ALVO Stock  USD 12.44  0.02  0.16%   

Insider

Sean Gaskell is Chief Officer of Alvotech
Age 42
Address 9, Rue de Bitbourg, Luxembourg City, Luxembourg, 1273
Phone354 422 4500
Webhttps://www.alvotech.com

Alvotech Management Efficiency

The company has return on total asset (ROA) of (0.0761) % which means that it has lost $0.0761 on every $100 spent on assets. This is way below average. Alvotech's management efficiency ratios could be used to measure how well Alvotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of November 2024, Return On Tangible Assets is likely to drop to -0.63. In addition to that, Return On Capital Employed is likely to drop to -0.54. At this time, Alvotech's Intangible Assets are very stable compared to the past year. As of the 21st of November 2024, Intangibles To Total Assets is likely to grow to 0.05, while Total Assets are likely to drop about 784 M.
Alvotech currently holds 1.08 B in liabilities. Alvotech has a current ratio of 0.84, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Alvotech's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Deepak MBADr Reddys Laboratories
49
P YugandharDr Reddys Laboratories
49
Peter LangoshAmphastar P
71
Gunupati BEDr Reddys Laboratories
64
Julien MeissonnierCatalent
N/A
Thomas HarveyAlkermes Plc
N/A
Michael GrippoCatalent
55
Jacob MBAAmphastar P
50
K SinghDr Reddys Laboratories
N/A
Roy MDPacira BioSciences,
62
Jonathan MDPacira BioSciences,
49
K KrishnanDr Reddys Laboratories
61
J CarrollCatalent
70
Kay SchmidtCatalent
61
Yongfeng ZhangAmphastar P
77
Erez MBADr Reddys Laboratories
56
Sanjay BTechDr Reddys Laboratories
56
Muthusamy RPhANI Pharmaceuticals
56
Steven EsqCatalent
61
MBA MBADr Reddys Laboratories
55
Floyd MDAlkermes Plc
87
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. The company was founded in 2013 and is headquartered in Reykjavik, Iceland. Alvotech is traded on NASDAQ Exchange in the United States. Alvotech (ALVO) is traded on NASDAQ Exchange in USA. It is located in 9, Rue de Bitbourg, Luxembourg City, Luxembourg, 1273 and employs 999 people. Alvotech is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Alvotech Leadership Team

Elected by the shareholders, the Alvotech's board of directors comprises two types of representatives: Alvotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alvotech. The board's role is to monitor Alvotech's management team and ensure that shareholders' interests are well served. Alvotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alvotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christina Siniscalchi, Interim Officer
Ming Li, Chief Officer
Sandra Casaca, Chief Officer
RoseMarie Ohlsson, Chief Officer
Anil Okay, Chief Officer
Giedrius Zunda, Chief Officer
Sean Gaskell, Chief Officer
Joel Morales, Chief Officer
Joseph McClellan, Chief Officer
Eva Gunnlaugsdottir, Vice Culture
Tanya Zharov, General Counsel
Faysal Kalmoua, COO Director
Mark Levick, Chief Officer
Sigridur Gudlaugsdottir, VP HR
Jenny Steingrimsdottir, Vice Culture
Robert Wessman, Founder Directors

Alvotech Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alvotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Alvotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alvotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alvotech will appreciate offsetting losses from the drop in the long position's value.

Moving together with Alvotech Stock

  0.75EWTX Edgewise TherapeuticsPairCorr

Moving against Alvotech Stock

  0.73TERN Terns PharmaceuticalsPairCorr
  0.71KURA Kura OncologyPairCorr
  0.65MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.64STOK Stoke TherapeuticsPairCorr
  0.57XFOR X4 PharmaceuticalsPairCorr
The ability to find closely correlated positions to Alvotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alvotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alvotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alvotech to buy it.
The correlation of Alvotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alvotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alvotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alvotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alvotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alvotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alvotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alvotech Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alvotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Alvotech Stock, please use our How to Invest in Alvotech guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alvotech. If investors know Alvotech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alvotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.70)
Earnings Share
(1.85)
Revenue Per Share
1.283
Quarterly Revenue Growth
43.997
Return On Assets
(0.08)
The market value of Alvotech is measured differently than its book value, which is the value of Alvotech that is recorded on the company's balance sheet. Investors also form their own opinion of Alvotech's value that differs from its market value or its book value, called intrinsic value, which is Alvotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alvotech's market value can be influenced by many factors that don't directly affect Alvotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alvotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alvotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alvotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.